ARTES successfully completed EU funded project Plurivax

ARTES Biotech­nol­o­gy explored very effec­tive in a SME con­sor­tium vac­cine devel­op­ments for vet­eri­nary appli­ca­tions.
Under the titel: “ERA-Net Euro­Trans­Bio-8: PLURIVAX, devel­op­ment of a virus-like-par­ti­cle (VLP) based vac­cine plat­form and sta­ble for­mu­la­tion espe­cial­ly suit­ed for the vet­eri­nary appli­ca­tions, the EU coop­er­a­tion was part of the 8th Euro­Trans­Bio call and was fund­ed in the time peri­od from June 2014 to Novem­ber 2017 by the Ger­man Fed­er­al Min­istry of Edu­ca­tion and Research (BMBF) and the Flan­ders (Bel­gium) agency for Inno­va­tion by Sci­ence and Tech­nol­o­gy (IWT).
For the devel­op­ment of vac­cines for human appli­ca­tions it is state of the art to use virus-like par­ti­cles (VLPs) as a vehi­cle. The use of these par­ti­cles has the advan­tage that they as such not being infec­tious but that they trans­port for­eign anti­gens in an ide­al way to the immune sys­tem. These very effec­tive and sim­ple mech­a­nism was the back­bone of the PLURIVAX project.
“As ini­tial nucle­us our pro­pri­etary VLP plat­form METAVAX® was tak­en. This plat­form has already been applied to the devel­op­ment of adju­vant-free vac­cine can­di­dates against dif­fer­ent human relat­ing dis­eases like flu, malar­ia and HIV”, Michael Pio­ntek, man­ag­ing direc­tor of ARTES stat­ed. “Our expres­sion host, the methy­lotroph­ic yeast Hansenu­la poly­mor­pha, is the pre­ferred tech­nol­o­gy for afford­able mass vac­ci­na­tion and is rec­om­mend­ed by the WHO for mass vac­ci­na­tions. Com­bi­na­tion of our both plat­forms build an excel­lent approach to low-cost mass pro­duc­tion of safe and effec­tive vac­cines.”
ARTES chose eight dif­fer­ent, large mol­e­c­u­lar weight anti­gens derived from four animal‑ infect­ing virus­es. The bovine viral diar­rhea virus (BVDV) as an impor­tant pathogen of cat­tle, also infect­ing sheep and pigs. The clas­si­cal swine fever virus (CSFV), which is acknowl­edged as a glob­al threat for swine and is list­ed as noti­fi­able ani­mal dis­eases by the World Orga­ni­za­tion for Ani­mal Health. The feline leukemia virus (FeLV) as a retro­virus threat­en­ing domes­tic cats and the west nile virus (WNV) which is a mos­qui­to vec­tor trans­mit­ted zoonot­ic virus of the Fla­viviri­dae fam­i­ly. WNV cir­cu­lates in birds as nat­ur­al hosts but can be trans­mit­ted to mam­mals includ­ing humans caus­ing west nile fever.
First results were released in a sci­en­tif­ic paper under the title “Estab­lish­ment of a yeast-based VLP plat­form for anti­gen pre­sen­ta­tion” (Wet­zel et al. Microb Cell Fact (2018) 17:17 )
and more infor­ma­tion could be get on https://doi.org/10.1186/s12934-018‑0868-0

Future steps are, that in close dis­cus­sions with glob­al vet­eri­nary vac­cine man­u­fac­tur­er, ARTES’ explores the com­mer­cial appli­ca­tion of the results and of the plat­form in gen­er­al.